This website is best viewed using the
horizontal display on your tablet device.

This website is best viewed using the
vertical display on your mobile device.

Metastatic Melanoma
Dosing for OPDIVO + YERVOY

Start with OPDIVO® (nivolumab) + YERVOY® (ipilimumab); maintain with OPDIVO monotherapy flexible dosing schedules1-3

OPDIVO®, OPDIVO® + YERVOY® Dosing Schedule
OPDIVO®, OPDIVO® + YERVOY® Dosing Schedule
  • Based on exploratory dose exposure response relationships for efficacy and safety, OPDIVO 240 mg
    q2w and 480 mg q4w are predicted to be similar3
  • Review the Full Prescribing Information for OPDIVO and YERVOY
  • The first dose of OPDIVO monotherapy should be administered after completing 4 doses of the OPDIVO
    and YERVOY combination1

*OPDIVO is administered as an intravenous infusion over 30 minutes.1

YERVOY is administered as an intravenous infusion over 90 minutes.2

q2w=every 2 weeks; q4w=every 4 weeks.

Select Important Safety Information

Infusion-Related Reactions
OPDIVO and YERVOY can cause severe infusion-related reactions. Discontinue OPDIVO and YERVOY in patients with severe (Grade 3) or life‐threatening (Grade 4) infusion-related reactions. Interrupt or slow the rate of infusion in patients with mild (Grade 1) or moderate (Grade 2) infusion‐related reactions. In patients receiving OPDIVO monotherapy as a 60-minute infusion, infusion-related reactions occurred in 6.4% (127/1994) of patients. In a separate trial in which patients received OPDIVO monotherapy as a 60-minute infusion or a 30-minute infusion, infusion-related reactions occurred in 2.2% (8/368) and 2.7% (10/369) of patients, respectively. Additionally, 0.5% (2/368) and 1.4% (5/369) of patients, respectively, experienced adverse reactions within 48 hours of infusion that led to dose delay, permanent discontinuation or withholding of OPDIVO. In melanoma patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, infusion-related reactions occurred in 2.5% (10/407) of patients. In separate Phase 3 trials of YERVOY 3 mg/kg and 10 mg/kg, infusion‐related reactions occurred in 2.9% (28/982) of patients.

Dosing for OPDIVO Monotherapy

OPDIVO® (nivolumab) has flexible dosing schedules to help meet the needs of patients1

Customize patient management with the choice of 2 dosing options1

Dosing Schedule for OPDIVO® Monotherapy
Dosing Schedule for OPDIVO® Monotherapy
30 Minute IV Infusion
30 Minute IV Infusion
  • Based on exploratory dose exposure response relationships for efficacy and safety, OPDIVO 240 mg q2w and 480 mg q4w are predicted to be similar3
  • No premedication required1
  • Dose until disease progression or unacceptable toxicity1
  • 240-mg/24-mL vial available1

Adjuvant Treatment of Melanoma

Q4W dosing offers a balance between patient and provider needs

Q4W Dosing Calendar
Q4W Dosing Calendar

Balance extended time between infusions with the confidence of regular monitoring

Help control patient adherence concerns with IV administration regardless of BRAF mutation status1,2.

  • Infusions may reduce adherence concerns and can be coordinated with patients’ monthly follow-up visits2
  • No in-home refrigeration, meal restrictions, and/or treatment pill burden for patients1,3†

Dose until disease recurrence or unacceptable toxicity for up to 1 year1

30 Minute IV Infusion
30 Minute IV Infusion

Dose until disease recurrence or unacceptable toxicity for up to 1 year1

  • HCPs have the flexibility of 2 IV dosing options infused over 30 minutes1,3

— q4w 480 mg

— q2w 240 mg

  • *This content is not intended to imply comparative efficacy between OPDIVO dosing schedules. Selection of approved dosing frequency should be
    based on independent clinical judgement.
  • Please see Sections 2.4 and 16 of the OPDIVO Full Prescribing Information for guidance on storage and refrigeration.
  • OPDIVO q4w dosing was approved for use in the US in 2018.

AE=adverse event; IV=intravenous; q2w=every 2 weeks; q4w=every 4 weeks.

Select Important Safety Information

Infusion-Related Reactions
OPDIVO and YERVOY can cause severe infusion-related reactions. Discontinue OPDIVO and YERVOY in patients with severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Interrupt or slow the rate of infusion in patients with mild (Grade 1) or moderate (Grade 2) infusion-related reactions. In patients receiving OPDIVO monotherapy as a 60-minute infusion, infusion-related reactions occurred in 6.4% (127/1994) of patients. In a separate trial in which patients received OPDIVO monotherapy as a 60-minute infusion or a 30-minute infusion, infusion-related reactions occurred in 2.2% (8/368) and 2.7% (10/369) of patients, respectively. Additionally, 0.5% (2/368) and 1.4% (5/369) of patients, respectively, experienced adverse reactions within 48 hours of infusion that led to dose delay, permanent discontinuation or withholding of OPDIVO. In melanoma patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, infusion-related reactions occurred in 2.5% (10/407) of patients. In separate Phase 3 trials of YERVOY 3 mg/kg and 10 mg/kg, infusion-related reactions occurred in 2.9% (28/982) of patients.

Learn About Safety
View Resources
References
  1. OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  2. YERVOY [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  3. Long GV, Tykodi SS, Schneider JG, et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol. 2018;29(11):2208-2213.
References
  1. OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  2. Seal BS, Anderson S, Shermock KM. Factors associated with adherence rates for oral and intravenous
    anticancer therapy in commercially insured patients with metastatic colon cancer. J Manag Care Spec
    Pharm.
    2016;22(3):227-235.
  3. Danesi R, Boni JP, Ravaud A. Oral and intravenously administered mTOR inhibitors for metastatic renal
    cell carcinoma: pharmacokinetic considerations and clinical implications. Cancer Treat Rev.
    2013;39(7):784-792.